This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chu, P. G. Articles by Weiss, L. M. Search for Related Content PubMed PubMed Citation Articles by Chu, P. G. Articles by Weiss, L. M.

(American Journal of Pathology. 1999;155:941-947.)
© 1999 American Society for Investigative Pathology

Regular Articles

Epstein-Barr Virus (EBV) Nuclear Antigen (EBNA)-4 Mutation in EBV-Associated Malignancies in Three Different Populations

Peiguo G. Chu^*, Karen L. Chang^*, Wen-Gang Chen^*, Yuan-Yuan Chen^*, Darryl Shibata, Kazukiko Hayashi, Carlos Bacchi^§, Maura Bacchi^§ and Lawrence M. Weiss^*

From the Division of Pathology,^*
City of Hope National Medical Center, Duarte, California; the Department of Pathology,
University of Southern California, Los Angeles, California; the Department of Pathology,
Okayama University Medical School, Okayama, Japan; and the Department of Pathology,^§
State University of Sao Paulo, Botucatu, Brazil

Different ethnic groups with a high human leukocyte antigen (HLA)-A11 prevalence have been shown to experience a high rate of Epstein-Barr virus (EBV) infection, EBV-associated malignancies, and Epstein-Barr nuclear antigen (EBNA)-4 mutations. The epitopes 399-408 and 416-424 of EBNA-4 are major antigenic epitopes that elicit an HLA-A11 cytotoxic T lymphocyte (CTL) response to EBV infection. Mutations selectively involving one or more nucleotide residues in these epitopes affect the antigenicity of EBNA-4, because the mutant EBV strains are not recognized by the HLA-A11-restricted CTLs. To investigate these mutations in common EBV-associated malignancies occurring in different populations, we studied the mutation rate of epitopes 399-408 and 416-424 of EBNA-4 in 25 cases of EBV-associated Hodgkin's disease (HD), nine cases of AIDS-related non-Hodgkin's lymphoma, and 37 cases of EBV-associated gastric carcinoma (GC) from the United States, Brazil, and Japan. We found one or more mutations in these two epitopes in 50% (6/12) of United States HD, 15% (2/13) of Brazilian HD, 50% (6/12) United States GC and 28% (7/25) Japanese GC, and 22% (2/9) of United States AIDS-lymphoma. Similar mutations were found in 30% (3/10) of United States reactive, 0% (0/6) of Brazilian reactive, and 25% (2/8) Japanese reactive tissues. The most frequent amino acid substitutions were virtually identical to those seen in previously reported isolates from EBV-associated nasopharyngeal carcinomas and Burkitt's lymphomas occurring in high prevalence HLA-A11 regions. However, only 2/28 (7%) mutations occurred in HLA-A11-positive patients. Our studies suggest that: 1) EBNA-4 mutations are a common phenomenon in EBV-associated HD, GC, and AIDS-lymphoma; 2) the mutation rate does not vary in these geographic areas and ethnic groups; 3) EBNA-4 mutations in EBV-associated United States and Brazilian HD, United States and Japanese GC, and United States AIDS lymphomas are not related to patients' HLA-A11 status.

This article has been cited by other articles:

				P. G. Chu, Y.-Y. Chen, W.-g. Chen, and L. M. Weiss No Direct Role for Epstein-Barr Virus in American Hepatocellular Carcinoma Am. J. Pathol., October 1, 2001; 159(4): 1287 - 1292. [Abstract] [Full Text]

				K Takada Epstein-Barr virus and gastric carcinoma Mol. Pathol., October 1, 2000; 53(5): 255 - 261. [Abstract] [Full Text]